A Multi-center, Open Label, Flexible Dose, Extension Study of Lurasidone Adjunctive to Lithium or Divalproex in Subjects With Bipolar I Disorder
Phase of Trial: Phase III
Latest Information Update: 24 Aug 2016
At a glance
- Drugs Lurasidone (Primary) ; Lithium; Valproate semisodium
- Indications Bipolar I disorders
- Focus Adverse reactions
- Acronyms PERSISTExt
- Sponsors Sunovion Pharmaceuticals
- 06 Aug 2015 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov..
- 12 Mar 2015 Planned End Date changed from 1 Apr 2015 to 1 Jul 2015 as reported by ClinicalTrials.gov.
- 12 Mar 2015 Planned primary completion date changed from 1 Feb 2015 to 1 Jul 2015 as reported by ClinicalTrials.gov.